文献速递神经核医学肿瘤 PET/CT

11C-蛋氨酸PET与解剖MRI在弥漫性内生性桥脑胶质瘤中的关联评估

Evaluation of 11C-Methionine PET and Anatomic MRI Associations in Diffuse Intrinsic Pontine Glioma.
PubMed 文献 · J Nucl Med · 2018-08-02

该前瞻性研究纳入22例新诊断的弥漫性内生性桥脑胶质瘤(DIPG)患儿,评估11C-蛋氨酸PET摄取指标与常规MRI指标及生存结局的关联。82%的基线扫描可见肿瘤摄取高于未受累脑组织,基线11C-蛋氨酸摄取可勾勒复发风险增高区域,但强度与均匀性指标未与治疗结局相关。

要点

  • 22例新诊断DIPG患儿中,18例(82%)基线11C-蛋氨酸PET显示摄取高于未受累脑组织。
  • 11C-蛋氨酸高摄取范围有限,11例(61%)阳性基线扫描中高摄取肿瘤不足25%。
  • 基线11C-蛋氨酸PET强度与均匀性指标未与生存结局相关。

核心结论

  • 大多数新诊断DIPG可通过11C-蛋氨酸PET成功显像。
  • 基线11C-蛋氨酸摄取可勾勒复发风险增高的区域,但本研究中的强度与均匀性指标未与DIPG患儿的治疗结局相关。

研究设计与样本

  • 前瞻性纳入22例新诊断DIPG患儿,接受基线11C-蛋氨酸PET/CT,其中17例在化疗或放疗后获得初始治疗反应扫描。
  • 由核医学医师与放射肿瘤科医师共识勾画三维感兴趣区,评估11C-蛋氨酸摄取强度与均匀性同生存的关联,以及摄取与常规MRI肿瘤指标随时间变化的关联。

主要发现

  • 基线扫描中18/22(82%)可见11C-蛋氨酸摄取高于未受累脑组织,初始反应扫描中15/17(88%)可见。
  • MRI定义的肿瘤内11C-蛋氨酸高摄取范围有限,18例阳性基线扫描中11例(61%)高摄取肿瘤不足25%。
  • 11C-蛋氨酸PET所示总肿瘤体积增加相对有限(17.2%;四分位距6.53%-38.90%),超出MRI定义肿瘤的摄取范围也有限(2.2%;四分位距0.55%-10.88%)。
  • 基线11C-蛋氨酸PET强度与均匀性指标未与生存结局相关,但初始11C-蛋氨酸高摄取与复发肿瘤重叠比例为100%。
  • 临床诊断为非典型DIPG与无进展生存期临界显著延长相关(P=0.07),但诊断时11C-蛋氨酸PET指标在非典型与典型DIPG间无显著差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The role of metabolic imaging in the diagnosis, treatment, and response assessment of diffuse intrinsic pontine glioma (DIPG) is poorly defined. We investigated the uptake of 11C-methionine in pediatric patients with newly diagnosed DIPG and evaluated the associations of 11C-methionine PET metrics with conventional MRI indices and survival outcomes. Methods: Twenty-two patients with newly diagnosed DIPG were prospectively enrolled on an institutional review board-approved investigational study of 11C-methionine PET. All patients underwent baseline 11C-methionine PET/CT, and initial treatment-response scans after chemotherapy or radiation therapy were obtained for 17 patients. Typical and atypical DIPGs were assessed clinically and radiographically and defined by multidisciplinary consensus. Three-dimensional regions of interest, reviewed by consensus between a nuclear medicine physician and a radiation oncologist, were delineated after coregistration of PET and MR images. Associations of 11C-methionine uptake intensity and uniformity with survival, along with associations between 11C-methionine uptake and conventional MRI tumor indices over time, were evaluated. 11C-methionine PET voxel values within regions of interest were assessed as threshold values across proportions of the study population, and 11C-methionine uptake at baseline was assessed relative to MRI-defined tumor progression. Results:11C-methionine uptake above that of uninvolved brain tissue was observed in 18 of 22 baseline scans (82%) and 15 of 17 initial response scans (88%). 11C-methionine avidity within MRI-defined tumor was limited in extent, with 11 of 18 positive baseline 11C-methionine PET scans (61%) showing less than 25% 11C-methionine-avid tumor. The increase in total tumor volume with 11C-methionine PET was relatively limited (17.2%; interquartile range, 6.53%-38.90%), as was the extent of 11C-methionine uptake beyond the MRI-defined tumor (2.2%; interquartile range, 0.55%-10.88%). Although baseline 11C-methionine PET intensity and uniformity metrics did not correlate with survival outcomes, initial 11C-methionine avidity overlapped with recurrent tumor in 100% of cases. A clinical diagnosis of atypical DIPG was associated with borderline significantly prolonged progression-free survival (P = 0.07), yet 11C-methionine PET indices at diagnosis did not differ significantly between atypical and typical DIPGs. Conclusion: Most newly diagnosed DIPGs are successfully visualized by 11C-methionine PET. Baseline 11C-methionine uptake delineates regions at increased risk for recurrence, yet intensity and uniformity metrics did not correlate with treatment outcomes in children with DIPG in this study.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Tinkle CL, Duncan EC, Doubrovin M, et al. Evaluation of 11C-Methionine PET and Anatomic MRI Associations in Diffuse Intrinsic Pontine Glioma. J Nucl Med. 2018. PMID: 30072503. doi:10.2967/jnumed.118.212514

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。